kabutan
N225

66,020.04

+2.81%

TOPIX

3,881.96

+1.35%

USDJPY

160.35

+0.25%

Oncolys BioPharma shares decline despite submission of clinical trial application for OBP-301 in new indication

Thu Jun 4, 2026 10:46 am JST Catalyst

Shares of Oncolys BioPharma Inc. <4588> traded softly on Thursday. Following Wednesday's market close, Oncolys BioPharma announced that it filed a clinical trial notification with the Pharmaceuticals and Medical Devices Agency (PMDA) for a Phase 1b/2a clinical trial of its oncolytic virus OBP-301 targeting the new indications of lower rectal cancer and anal cancer. The study will evaluate the efficacy and safety of OBP-301 combined with preoperative chemoradiotherapy. Oncolys BioPharma aims to begin dosing during the fiscal year ending December 2026. Although the stock opened higher on the disclosure, buying momentum stalled, and the shares faced profit-taking pressure.

Source: MINKABU PRESS

*Translated by generative AI. Click here for the original article.